07/10/2026
FOUR SUSPENSIONS LATER: WHEN DISCUSSION BECOMES THE THREAT
You know you may be onto something—or at least touching a very protected nerve—when a technology giant repeatedly restricts your ability to participate in the conversation.
Continue to read but we have migrated to Skool:
https://www.skool.com/the-peptide-tactical-playbook-7972/about?ref=c6da54f2d1b444e1ac3b78b48f287f75
I am currently finishing my fourth back-to-back Meta suspension. For four consecutive cycles, I have been prevented from posting in groups, contributing to discussions, or openly talking about peptides. At this point, it is difficult to dismiss the pattern as an isolated moderation mistake.
Let me be precise about what I am—and am not—claiming.
I do not possess evidence that a pharmaceutical executive personally contacted Meta and ordered my account to be restricted. Pretending otherwise would weaken the argument. The deeper and more defensible concern is that no direct order may be necessary. Meta’s broad pharmaceutical-content policies, opaque enforcement systems, the FDA’s increasingly restrictive approach to compounded substances, and the pharmaceutical industry’s enormous political influence can operate independently while still producing the same predictable result:
Independent discussion becomes more difficult, affordable access becomes narrower, and control moves toward institutions capable of navigating—and profiting from—the approved system.
Meta’s policies are broad enough to suppress legitimate education
Meta prohibits attempts to buy, sell, trade, transfer, or distribute certain pharmaceutical products. That is understandable. A responsible platform should prevent fraudulent sales, counterfeit products, dangerous instructions, and illegal transactions.
However, Meta’s own policy also recognizes that discussions concerning the affordability, accessibility, or efficacy of prescription drugs in a medical context may be legitimate. That distinction is critical because discussing a substance is not automatically the same as selling it, and educating adults is not the same as facilitating an unlawful transaction.
The problem is enforcement.
Meta’s Oversight Board has already documented cases in which legitimate medicine-related reporting was incorrectly removed under the company’s Restricted Goods and Services policy. In one group of cases, six pieces of content were removed and an entire page was unpublished. The Board described broader concerns involving over-enforcement, limitations in automation and human judgment, inadequate appeals, and systemic weaknesses in identifying moderation errors.
That matters because a temporary suspension is not merely an inconvenience. It removes a person from the public square. It limits the ability to answer questions, correct misinformation, provide context, and participate in communities that person helped build.
When enforcement repeatedly fails to distinguish between education, advocacy, personal experience, medical discussion, and commercial activity, the policy stops functioning like a safety mechanism and starts functioning like a censorship mechanism—whether that outcome was intentional or not.
The pharmaceutical-industrial complex does not require a secret conspiracy
People hear the phrase “pharmaceutical-industrial complex” and immediately imagine a hidden room where corporations, regulators, technology companies, and politicians coordinate every decision.
The reality is usually more sophisticated.
Power does not always operate through explicit commands. It frequently operates through aligned incentives. Pharmaceutical manufacturers want to protect intellectual property, preserve market exclusivity, limit unregulated competition, and maintain control over distribution. Regulators are responsible for safety and quality but also operate inside a funding and policy structure partially dependent upon the industries they regulate. Social-media platforms want to reduce legal exposure and therefore tend to over-enforce broad policies involving drugs. Physicians, pharmacies, insurers, manufacturers, telehealth companies, and pharmacy-benefit managers all occupy profitable positions within the authorized distribution chain.
Each institution can claim that it is simply following its own rules. Yet the cumulative outcome remains the same: information and access become increasingly centralized.
That is how structural power works. No single conspiracy is required when every major incentive points in the same direction.
Why the FDA can appear to be “pay to play”
Calling the FDA literally corrupt would require evidence of criminal conduct. I am not making that legal allegation. However, Americans are entirely justified in questioning a regulatory structure in which the regulated industry provides such a substantial share of the regulator’s resources.
For fiscal year 2026, the FDA requested a $6.8 billion budget consisting of approximately $3.2 billion in congressional budget authority and $3.6 billion in user fees. The FDA also acknowledges that its performance budget combines taxpayer appropriations with industry fees, that these fees are negotiated with manufacturers and approved by Congress, and that performance goals are connected to review timelines and other metrics.
User fees do not automatically prove that individual FDA scientists or reviewers are compromised. They were created to provide staffing and accelerate reviews. Nevertheless, the structure creates an unavoidable question:
How independent can a regulator appear when a major portion of its operating capacity is financed by the companies seeking its decisions?
The concern becomes more serious when conflict-of-interest procedures lack full transparency. In March 2026, the Government Accountability Office reported that the FDA had not publicly disclosed enough information about how it determines certain financial conflicts involving advisory-committee participants. The GAO also found that required guidance remained unfinished more than 13 years after Congress required it and recommended greater public disclosure to provide assurance that potential industry influence was being properly managed.
That is why the phrase “pay to play” resonates with so many people. It does not necessarily mean an envelope of cash is exchanged for a predetermined vote. It describes a system in which access, review capacity, regulatory timelines, intellectual property, lobbying, and market entry are heavily influenced by money.
The appearance of dependency is itself corrosive. Public trust requires more than assurances that the process is independent. It requires a system designed to demonstrate that independence.
Big Pharma’s political influence is documented—not imagined
Pharmaceutical influence over government policy is not a fringe theory. Lobbying is a legal, organized, extensively funded process specifically intended to influence legislation, appropriations, regulation, taxation, reimbursement, patent protection, and market access.
A peer-reviewed analysis published in JAMA Internal Medicine found that the pharmaceutical and health-product industry spent approximately $4.7 billion lobbying the federal government between 1999 and 2018, averaging roughly $233 million annually during that period. The industry also directed substantial resources toward political campaigns and advocacy organizations.
That influence has not disappeared. Pharmaceutical and technology interests remained among the largest lobbying forces in Washington during 2025, as companies sought to shape drug-pricing policy, compounding rules, reimbursement structures, patent protections, and regulatory implementation.
Lobbying does not prove that every government decision is purchased. It does prove that large corporations possess access, expertise, legal resources, relationships, and political leverage that ordinary patients, independent researchers, small laboratories, educators, and community advocates cannot possibly match.
When one side arrives with hundreds of lobbyists, regulatory attorneys, political consultants, economic studies, campaign relationships, and billions of dollars at stake, while the public is represented by scattered comments and individual advocates, that is not an equal policy debate.
It is institutional asymmetry.
The pricing problem cannot be ignored
The argument becomes even more troubling when access restrictions are defended as public protection while the approved alternatives remain financially inaccessible.
I would not claim that every peptide carries a universal 4,000% markup, because pricing varies by substance, manufacturing standard, testing, formulation, clinical development, intellectual property, distribution, insurance coverage, and dispensing channel. However, there is credible evidence that the distance between estimated production-based costs and American market prices can be enormous.
A 2024 JAMA Network Open economic evaluation estimated sustainable cost-based monthly prices for GLP-1 receptor agonists ranging from approximately $0.75 to $72.49, depending on the product and formulation, and concluded that these estimated prices were substantially below market prices in most of the countries examined.
Therefore, describing certain pharmaceutical markups as reaching into the thousands of percent is not inherently absurd. What would be irresponsible is treating one estimate as universally applicable to every peptide or medication.
The broader point remains undeniable: when lower-cost pathways are restricted while high-priced branded pathways are protected, patients have every right to ask whether the policy is primarily protecting public health, protecting established markets, or attempting to accomplish both without honestly acknowledging the conflict.
Peptide access is being decided right now
This is not a hypothetical future battle.
The FDA has scheduled a July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting to evaluate substances related to BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon for potential inclusion on the 503A bulk-drug-substances list. The uses under evaluation include wound healing, inflammatory conditions, obesity, osteoporosis, insomnia, migraine, cerebral ischemia, and other applications.
The agency has also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug-substances list, stating that it did not identify sufficient clinical need for outsourcing facilities to compound those drugs from bulk substances when approved products are available.
The FDA has a legitimate responsibility to address contamination, inaccurate labeling, sterility failures, inconsistent potency, unsupported medical claims, and unsafe manufacturing. Those are real issues, and peptide advocates should not pretend otherwise.
But safety cannot become an all-purpose justification for eliminating competition, suppressing discussion, or forcing every consumer into the most expensive available channel. Regulation should establish standards for identity, purity, sterility, potency, labeling, adverse-event reporting, and truthful communication. It should not automatically be used to make affordable access impossible.
The answer is transparency—not silence
Not every peptide claim is accurate. Not every product is safe. Not every protocol is supported by strong human evidence. Responsible advocates should openly acknowledge uncertainty, distinguish clinical evidence from animal research, explain risk, demand independent testing, and refuse to present personal outcomes as universal medical proof.
But those limitations are arguments for better education, not selective silence.
The public deserves clear moderation rules, meaningful human review, proportionate penalties, transparent appeals, fully disclosed regulatory conflicts, independently funded oversight, rigorous quality standards, and an honest national conversation about pharmaceutical pricing and access.
To ordinary Americans, the current outcome can feel criminal—even when the mechanisms producing it are technically legal. Information is restricted. Competition is narrowed. Affordable alternatives disappear. The same substances can then return through approved institutional channels carrying dramatically higher prices.
That is not a sustainable model of public trust.
So yes, I am finishing my fourth consecutive suspension. But I am not going to stop asking questions, examining the evidence, challenging unequal systems, or advocating for responsible peptide education.
Silencing a discussion does not settle the science.
Restricting an advocate does not eliminate the evidence.
And protecting an institution from scrutiny does not protect the public.
— Mark Williams
Founder, The Peptide Tactical Playbook
